Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 783-786

  Qian, Jun ^a   Qian, Zhen ^a   Lin, Jiang ^a   Yao, Dong ming ^a   Chen, Qin ^a   Li, Yun ^a   Ji, Run bi ^a   Yang, Jing ^a   Xiao, Gao fei ^a   Wang, Ya li ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; GRAF gene; Methylation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHINESE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENETIC ANALYSIS; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GRAF GENE; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GTPASE-ACTIVATING PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 79955601719     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.013     Document Type: Article

References (30)

1. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Renneville A., Roumier C., Biggio V., Nibourel O., Boissel N., Fenaux P., et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
3. Mrózek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification. Blood 2007, 109:431-448.
4. Pabst T., Mueller B.U. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 2007, 26:6829-6837.
5. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007, 7:823-833.
6. Scholl C., Gilliland D.G., Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008, 35:336-345.
7. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Prog 2008, 400-411.
8. Plass C., Oakes C., Blum W., Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol 2008, 35:378-387.
9. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
10. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138:3-11.
11. Jost E., Galm O. EHA Scientific Workshop Report: the role of epigenetics in hematological malignancies. Epigenetics 2007, 2:71-79.
12. Hildebrand J.D., Taylor J.M., Parsons J.T. An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol 1996, 6:3169-3178.
13. Sahai E., Olson M.F., Marshall C.J. Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001, 20:755-766.
14. Borkhardt A., Bojesen S., Haas O.A., Fuchs U., Bartelheimer D., Loncarevic I.F., et al. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000, 97:9168-9173.
15. Bojesen S.E., Ammerpohl O., Weinhäusl A., Haas O.A., Mettal H., Bohle R.M., et al. Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome. Br J Cancer 2006, 94:323-332.
16. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
17. Karlsson R., Pedersen E.D., Wang Z., Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009, 1796:91-98.
18. Benitah S.A., Valerón P.F., van Aelst L., Marshall C.J., Lacal J.C. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004, 1705:121-132.
19. Aznar S., Fernández-Valerón P., Espina C., Lacal J.C. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 2004, 206:181-191.
20. Vidal A., Millard S.S., Miller J.P., Koff A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J Biol Chem 2002, 277:16433-16440.
21. Seasholtz T.M., Zhang T., Morissette M.R., Howes A.L., Yang A.H., Brown J.H. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001, 89:488-495.
22. Olson M.F., Paterson H.F., Marshall C.J. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998, 394:295-299.
23. Liberto M., Cobrinik D., Minden A. Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene 2002, 21:1590-1599.
24. Vega F.M., Ridley A.J. Rho GTPases in cancer cell biology. FEBS Lett 2008, 582:2093-2101.
25. Sieg D.J., Hauck C.R., Ilic D., Klingbeil C.K., Schaefer E., Damsky C.H., et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2:249-256.
26. Zhao J., Guan J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009, 28:35-49.
27. Recher C., Ysebaert L., Beyne-Rauzy O., Mansat-De Mas V., Ruidavets J.B., Cariven P., et al. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 2004, 64:3191-3197.
28. Tavernier-Tardy E., Cornillon J., Campos L., Flandrin P., Duval A., Nadal N., et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009, 33:764-768.
29. Le Y., Xu L., Lu J., Fang J., Nardi V., Chai L., Silberstein L.E. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am J Hematol 2009, 84:273-278.
30. Tyner J.W., Walters D.K., Willis S.G., Luttropp M., Oost J., Loriaux M., et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008, 111:2238-2245.